Multicenter study to assess the in vitro activity of tigecycline by disk diffusion test against clinical isolates from Argentina

Chemotherapy

Volumn 55, Issue 1, 2008, Pages 20-27

  Fernández Canigia, Liliana ^a   Kaufman, Sara ^b   Lanata, Liliana ^c   Vay, Carlos ^d   Giovanakis, Marta ^e   Bantar, Carlos ^f   Badia, M ^g   Bottiglieri, M ^h   Cattani, A ⁱ   Couto, E ^j   Di Martino, A ^k   Genero, F ^l   Gonzalez L ^m   Greco, G ⁿ   Sandorin, R ⁱ   Santana, G ^o   Scapini, J ^p   Stepanik, D ⁱ   Sucari, A ^q   Vilches, V ^r   Wolf, L ^s   more..

^a HOSPITAL ALEMÁN   (Argentina)

^b Hospital Fernández

^c Clínica San Camilo

^d Hospital Británico

^e Sanatorio Mater Dei   (Argentina)

^f Laboratorio Domingo I Nanni   (Argentina)

^g HOSPITAL GENERAL DE AGUDOS DR COSME ARGERICH   (Argentina)

^h Hospital Allende   (Mexico)

ⁱ Sanatorio de la Trinidad   (Argentina)

^j HOSPITAL FRANCÉS   (Argentina)

^k Sanatorio Mitre   (Argentina)

^l Sanatorio Las Lomas   (Argentina)

^m Instituto del Diagnostico   (Argentina)

ⁿ HOSPITAL ITALIANO DE BUENOS AIRES   (Argentina)

^o Sanatorio San Lucas   (Argentina)

^p Idymic   (Argentina)

^q Sanatorio Otamendi   (Argentina)

^r UNIVERSIDAD AUSTRAL   (Argentina)

^s Infectious Diseases Section   (Argentina)

more..

Author keywords

Disk diffusion; Multiresistant organisms; Tigecycline

Indexed keywords

AMIKACIN; AMPICILLIN; BETA LACTAMASE; CEFEPIME; CEFOTAXIME; CEFOXITIN; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; COTRIMOXAZOLE; ERYTHROMYCIN; GENTAMICIN; IMIPENEM; MEROPENEM; METICILLIN; MINOCYCLINE; OXACILLIN; PIPERACILLIN PLUS TAZOBACTAM; RIFAMPICIN; SULTAMICILLIN; TEICOPLANIN; TIGECYCLINE; VANCOMYCIN;

ACINETOBACTER; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARGENTINA; ARTICLE; BACTERIUM ISOLATE; CITROBACTER; COAGULASE NEGATIVE STAPHYLOCOCCUS; CONTROLLED STUDY; DISK DIFFUSION; ENTEROBACTERIACEAE; ENTEROCOCCUS; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; GRAM POSITIVE BACTERIUM; IN VITRO STUDY; KLEBSIELLA PNEUMONIAE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SERRATIA; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ANTI-BACTERIAL AGENTS; ARGENTINA; DISK DIFFUSION ANTIMICROBIAL TESTS; DRUG RESISTANCE, BACTERIAL; DRUG RESISTANCE, MULTIPLE; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HUMANS; MINOCYCLINE;

EID: 54949111715     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000167788     Document Type: Article

References (23)

1. Bradford PA, Weaver-Sands DT, Petersen PJ: In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections. Clin Infect Dis 2005;41:S315-S332.
2. Petersen PJ, Jacobus NV, Weiss WJ, Sum PE, Testa RT: In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936). Antimicrob Agents Chemother 1999;43:738-744.
3. Draghi DC, Tench S, Dowzicky MJ, Sahm DF: Baseline in vitro activity of tigecycline among key bacterial pathogens exhibiting multidrug resistance. Chemotherapy 2008;54:91-100.
4. Livermore DM: Tigecycline: what is it, and where should it be used? J Antimicrob Chemother 2005;56:611-614.
5. Babinchak T, Ellis-Grosse E, Dartois N, Rose G, Loh E: The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin Infect Dis 2005;41:354-367.
6. Breedt J, Teras J, Gardovskis J, Maritz F, Vaasna T, Roos DP, Gioud-Paquet M, Dartois N, Ellis-Grosse EJ, Loh E, Tigecycline 305 cSSSI Study Group: Safety and efficacy of tigecycline in treatment of skin and skin-structure infections: results of a double-blind phase 3 comparison study with vancomycin-aztreonam. Antimicrob Agents Chemother 2005;49:4658-4666.
7. Grosse-Ellis E, Babinchak T, Dartois N, Rose G, Loh E: The efficacy and safety of tigecycline in the treatment of skin and skin structure infections. Clin Infect Dis 2005;41:341-353.
8. Murray PR, Baron EJ, Jorgensen JH, Pfaller MA, Yolken RH: Manual of Clinical Microbiology. Washington, ASM Press, 2003.
9. Clinical and Laboratory Standards Institute: Performance Standards for Antimicrobial Disk Susceptibility Tests; Approved Standard, ed 9. Wayne, CLSI, 2006, M2-A9.
10. Clinical and Laboratory Standards Institute: Performance Standards for Antimicrobial Susceptibility Testing. 16th Informational Supplement CLSI. Wayne, CLSI, 2006, M100-S16.
11. Jones RN, Ferraro MJ, Reller LB, Schreckenberger PC, Swenson JM, Sander HS: Multicenter studies of tigecycline disk diffusion susceptibility results for Acinetobacter spp. J Clin Microbiol 2007;45:227-230.
12. Rice LB: Challenges in identifying new antimicrobial agents effective for treating infections with Acinetobacter baumannii and Pseudomonas aeruginosa . Clin Infect Dis 2006;43:S100-S105.
13. Betriu C, Rodriguez-Avial I, Sánchez BA, Gómez M, Alvarez J, Picazo JJ, Spanish Group of Tigecycline: In vitro activities of tigecycline (GAR-936) against recently isolated clinical bacteria in Spain. Antimicrob Agents Chemother 2002;46:892-895.
14. Waites KB, Duffy LB, Dowzicky MJ: Antimicrobial susceptibility among pathogens collected from hospitalized patients in the United States and in vitro activity of tigecycline, a new glycylcycline. Antimicrob Agents Chemother 2006;50:3479-3484.
15. Roveta S, Marchese A, Debbia EA: Tigecycline in vitro activity against gram-negative and gram-positive pathogens collected in Italy. Chemotherapy 2008;54:43-49.
16. Bantar C, Famiglietti A, Goldberg M: Three-year surveillance study of nosocomial bacterial resistance in Argentina. The Antimicrobial Committee; and the National Surveillance Program (SIR) Participants Group. Int J Infect Dis 2000;4:85-90.
17. PER-2. Antimicrob Agents Chemother 2007;51:2359-2365.
18. Quinteros M, Radice M, Gardella N, Rodriguez MM, Costa N, Korbenfeld D, Couto E, Gutkind G, Microbiology Study Group: Extended-spectrum β-lactamases in Enterobacteriaceae in Buenos Aires, Argentina, Public Hospitals. Antimicrob Agents Chemother 2003;47:2864-2867.
19. Garnacho-Montero J, Ortiz-Leyba C, Jiménez-Jiménez FJ, Barrero-Almodóvar AE, García-Garmendia JL, Bernabeu-Wittel M, Gallego-Lara SL, Madrazo-Osuna J: Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clin Infect Dis 2003;36:1111-1118.
20. Pasteran F, Rapoport M, Petroni A, Faccone D, Corso A, Galas M, et al: Emergence of PER-2 and VEB-1a in Acinetobacter baumannii strains in the Americas. Antimicrob Agents Chemother 2006;50:3222-3224.
21. Pachon-Ibanez ME, Jiménez-Mejias ME, Pichardo C, Llanos AC, Pachon J: Activity of tigecycline (GAR-936) against Acinetobacter baumannii strains, including those resistant to imipenem. Antimicrob Agents Chemother 2004;48:4479-4481.
22. Casellas JM, Bantar C, Duret F, Argentinean Collaborative Test Group: Comparative in vitro activity of tigecycline against aerobic and facultative isolates recovered from hospitalized patients: an Argentinean multicenter study. J Chemother 2007;19:27-32.
23. Agwuh KN, MacGowan R: Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines. J Antimicrob Chemother 2006;58:256-265.